Interim Report 2026
Filed with HKEX · Stock code 455 · · 54 pages · English and Chinese
2 Corporate Information 3 Management Discussion and Analysis 8 Disclosure of Interests and Other Information 12 公司資料 13 管理層討論與分析 18 權益披露及其它資料 22 Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 簡明綜合損益及其它全面收益表 24 Condensed Consolidated Statement of Financial Position 簡明綜合財務狀況表 26 Condensed Consolidated Statement of Changes in Equity 簡明綜合權益變動表 27 Condensed Consolidat
Tianda Pharmaceuticals Ltd. on 6ix
Earlier from Tianda Pharmaceuticals
- Tianda Pharma Announces 2022/23 Interim Results
- Tianda Pharmaceuticals Annual Results 2022
- Acquiring Xiaoer Qingre Zhike granule, Tianda Pharmaceuticals continues to broaden its product mix and perfect its Chinese medicine whole industry chain layout
- Tianda Pharmaceuticals acquires Yeung & Young Medicare and Qi's Living, establishing long-term cooperation
Later from Tianda Pharmaceuticals
- Notification Letter and Reply Form to Registered Shareholders
- Notification Letter and Request Form to Non-Registered Shareholders
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September, 2026
Follow Tianda Pharmaceuticals into a list and get an email when it puts out news.
Follow Tianda Pharmaceuticals